Interim Results

RNS Number:8189O
Cytomyx Holdings PLC
02 January 2007

                              Cytomyx Holdings Plc

           Interim results for the six months ended 30 September 2006



CHAIRMAN'S STATEMENT



Cytomyx PLC is going through significant changes. In November, I was named by
the board to take charge of the company. Although this company had significant
financial difficulties, I believe there are interesting business opportunities
moving forward.



With the complete of human genome project, the field of individualised medicine
is increasing becoming a clinical reality. The centrepiece of individualised
medicine is the discovery and validation of clinically important biomarkers
which can improve significantly the diagnosis and treatment of various diseases.



Cytomyx LLC, the remaining core business unit of Cytomyx PLC, is uniquely
positioned as a potential leader in the field of biomarker discovery and
validation. The company has collected over 200,000 clinically important human
tissue samples over the years and has over 100 customers who rely on Cytomyx's
tissue repository and clinical data for biomarker discovery and validation.



We are planning to change our core business of a pure biorepository into a human
tissue based biomarker discovery and validation company. For this reason, we are
positioning the company as "Cytomyx-The Biomarker Company". This is a very
exciting and dynamic market. We believe that there will be significant value to
be created in this field.



Wei-Wu He, Ph.D.
Chairman and CEO


CONSOLIDATED PROFIT AND LOSS ACCOUNT
Six months ended 30 September 2006
                                                                                           2006 (unaudited)
                                                                                                          #
                                                             Notes
TURNOVER
Existing operations                                                                                 468,048

Turnover - continuing operations                                                                    468,048

Turnover                                                                                            468,048

Cost of sales                                                                                   (1,242,325)

Gross profit                                                                                      (774,277)

Administrative expenses                                                                         (1,411,965)

OPERATING LOSS
Existing operations                                                                             (2,173,757)

Operating loss                                                                                  (2,173,757)

LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION                                                     (2,173,757)

Tax on loss on ordinary activities                                                                   43,475

LOSS FOR THE FINANCIAL PERIOD                                                                   (2,130,282)


Loss per ordinary share (pence)                                  2                                   (3.66)

Diluted loss per ordinary share (pence)                          2                                   (3.66)

CONSOLIDATED STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
Six months ended 30 September 2006
                                                                                           2006 (unaudited)
                                                                                                          #

Loss for the year                                                                               (2,130,282)
Currency translation difference                                                                    (20,249)

TOTAL GAINS AND LOSSES RECOGNISED IN THE YEAR                                                   (2,150,531)

CONSOLIDATED BALANCE SHEET
September 30, 2006
                                                                                           2006 (unaudited)
                                                                                                          #
FIXED ASSETS
Intangible assets                                                                                   847,686
Tangible assets                                                                                     368,903

                                                                                                  1,216,589

CURRENT ASSETS
Stocks                                                                                              396,518
Debtors - Due with one year                                                                         126,379
Cash at bank and in hand                                                                             98,748

                                                                                                    621,645
CREDITORS: amounts falling due
within one year                                                                                   (457,798)

NET CURRENT ASSETS                                                                                  163,847

TOTAL ASSETS LESS CURRENT LIABILITIES                                                             1,380,436

NET ASSETS                                                                                        1,380,436


CAPITAL AND RESERVES
Called up share capital                                                                           1,546,456
Share premium account                                                                             9,072,552
Share capital to be issued                                                                          148,750
Merger reserve                                                                                      945,000
Profit and loss account                                                                        (10,332,322)

EQUITY SHAREHOLDERS' FUNDS                                                                        1,380,436

CONSOLIDATED CASH FLOW STATEMENT
Six months ended 30 September 2006
                                                                                           2006 (unaudited)
                                                                                                          #

Net cash outflow from operating activities                                                      (1,817,261)

Returns on investments and servicing of finance                                                   (310,149)

Taxation                                                                                             55,654

Capital expenditure and financial investment                                                      (112,982)

Net cash outflow before management of liquid resources                                          (2,184,738)
and financing

Financing                                                                                           875,474

Decrease in cash in the year                                                                    (1,309,264)


RECONCILIATION OF OPERATING LOSS TO NET CASH OUTFLOW FROM OPERATING ACTIVITIES
                                                                                           2006 (unaudited)
                                                                                                          #


Operating loss                                                                                  (2,130,282)
Depreciation charge                                                                                  21,518
Amortisation of goodwill and intangibles                                                              4,913
Decrease  in debtors                                                                              1,068,244
Increase in creditors                                                                             (781,654)

Net cash outflow from operating activities                                                      (1,817,261)



1. BASIS OF PREPARATION

These interim financial statements for the twelve  months ended 30 September
2006 and 2005 are unaudited and do not constitute statutory financial statements
within the meaning of section 240 of the Companies Act 1985.

These interim financial statements comply with relevant accounting standards and
have been prepared on a consistent basis using accounting policies set out in
the 2005 Annual Report.



2. LOSS PER ORDINARY SHARE

The loss per share is based on the weighted average number of shares and is
presented as if the share consolidation had happened at the beginning of the
first period presented within these interim financial statements.



The calculations of basic and diluted loss per ordinary share are based on a
loss of #2,130,282 (30 September 2005 - #2,307,595) and on 58,125,182 (30
September 2004 - 47,974,948) ordinary shares being the weighted average number
of ordinary shares in issue during the period.



3. RELATED PARTY TRANSACTIONS

On 15 September 2005 the group sold 100% of its holding in Cambridge Bioscience
Limited to A Seeley (a former director) for the exchange of #164,034 of cash and
the cancellation of loans amounting to #727,975, which were payable to A Seeley.
The loss on disposal created by the sale of Cambridge Bioscience Limited
amounted to #769,521.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IR OKDKDPBKDKDK